News Release

Research Article Cites Cleanascite™ for Purification of Coupled Perfluorocarbon Nanoparticles

MONMOUTH JUNCTION, NJ, July 17, 2023 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their lipid binding technology for purifying coupled nanoparticles.

The citation is:

Vargas, Ian, et al. "Simultaneous Inhibition of Thrombosis and Inflammation Is Beneficial in Treating Acute Myocardial Infarction." International journal of molecular sciences 24.8 (2023): 7333.

Myocardial ischemia reperfusion injury (IRI) in acute coronary syndromes is a condition in which ischemic/hypoxic injury to cells subtended by the occluded vessel continues despite successful resolution of the thrombotic obstruction. In this work, a Perfluorocarbon nanoparticles-based therapeutic strategy was investigated for local thrombin inhibition that may simultaneously mitigate both thrombosis and inflammatory signaling pathways to limit myocardial IRI. The article states “The extent of an irreversible thrombin inhibitor, PPACK (Phe[D]-Pro-Arg-Chloromethylketone) coupling was determined by reverse-phase HPLC quantification of uncoupled PPACK after centrifugation of nanoparticles with Cleanascite lipid adsorption reagent”. The article concludes that thrombin inhibition with an extraordinarily potent but locally acting agent, suggested a critical role for thrombin and a promising therapeutic strategy in cardiac IRI. 

“It is great to see yet another completely different use of Cleanascite™. Here it is employed to efficiently removed lipid-bound nanoparticles to determine coupling efficiency of the thrombin inhibitor under investigation.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords

acute myocardial infarction, thrombosis, inflammation, inflammasome, perfluorocarbon nanoparticles, lipid binding, Cleanascite™.

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For Business Development, Contact:
Matthew Kuruc 732-274-2866 mkuruc@biotechsupportgroup.com